MetaCap

Embecta Corp. (EMBC)

NASDAQ: EMBCHealth CareMedical/Dental InstrumentsUSD

6.02-0.17 (-2.75%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EMBC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$341.09M
Dividend yield
7.64% ($0.46)
Ex-dividend date
Aug 27, 2026
52-week range
2.77 – 14.78
Day range
5.90 – 6.40
Volume / Avg
862.80K / 1.01M
Beta
—
Next earnings
Nov 24, 2026

52-week range

$2.77$14.78

EMBC stock today

Shares of Embecta (EMBC) finished lower on Nov 20 at $6.02, a drop of 2.75% or $0.17 per share, versus the S&P 500's 3.70% decline. Shares are 59.3% below their 52-week high of $14.78, set on Nov 21, 2025 and 117.3% above the 52-week low of $2.77, in the middle of the past year's range. EMBC is down 49.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 58.7%.

At 4.1x trailing earnings, Embecta trades below the peer-group median of 32.6x. Its forward P/E of 3.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Nov 24 before the market opens; analysts expect EPS of $0.31. Embecta pays an annual dividend of $0.46 per share, a 7.64% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Embecta

Company profile

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors.

Industry
Medical/Dental Instruments
CEO
Mr. Devdatt Kurdikar Ph.D.
Headquarters
Parsippany, NJ
Employees
1,850

Financial highlights

Full financials

In fiscal 2025, Embecta generated $1.08 billion in revenue, down 3.8% from fiscal 2024, its first annual decline since 2023. Net income was $95.4 million (+21.8% year over year), for a net margin of 8.8% versus a median of 19.8% in the prior 5 years. Gross margin was 62.6% (down from 65.5%) and operating margin 22.4%.

Embecta annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.08B$1.12B$1.12B$1.13B$1.17B
Growth-3.80%+0.21%-0.77%-3.07%+7.35%
Net income$95.40M$78.30M$70.40M$223.60M$414.80M
EPS (diluted)$1.62$1.34$1.22$3.89$7.28

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$4.00-33.55%

  • Strong buy 0
  • Buy 0
  • Hold 3
  • Sell 0
  • Strong sell 1

Target range

Low $3.00High $5.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 24, 2026
EPS estimate
$0.31
Last reported (Q3 2026)
Aug 7, 2026
EPS actual vs est.
$0.36 vs —

Dividends

Dividend history
Annual dividend
$0.46
Last payment
$0.01
Ex-dividend date
Aug 27, 2026

EMBC news

All EMBC news

Embecta peers

Health Care sector
EMBC peer companies
CompanyPrice% ChgMarket capCompare
BWAYBrainsWay Ltd. ADR8.48-2.86%$341.35Mvs EMBC
CERSCerus Corporation1.85-2.63%$373.62Mvs EMBC
MOBIMobia Medical Inc.11.85-0.08%$394.50Mvs EMBC
INFUInfuSystems Holdings Inc.14.35+2.06%$287.48Mvs EMBC
TMCITreace Medical Concepts Inc.4.31-0.92%$282.56Mvs EMBC
NPCENeuropace Inc.7.95-2.33%$273.89Mvs EMBC
SIShoulder Innovations Inc.20.15-0.79%$421.58Mvs EMBC
SSIISS Innovations International Inc.1.27-0.78%$254.86Mvs EMBC

Indexes, lists and sector

Embecta stock FAQ

What is Embecta's stock price today?

EMBC last traded at $6.02 as of Nov 20, 4:00 PM EST, down 2.75% on the day. Prices are delayed at least 15 minutes.

Does Embecta pay a dividend?

Yes. Embecta pays $0.46 per share annually, a 7.64% yield. The most recent dividend of $0.01 had an ex-dividend date of Aug 27, 2026.

When is Embecta's next earnings date?

Embecta is expected to report earnings on Tuesday, November 24, 2026. Analysts expect EPS of $0.31.

What is EMBC's P/E ratio?

EMBC trades at a trailing P/E ratio of 4.10 and a forward P/E of 3.42, compared with a median of 32.6 for its closest peers.

Who is Embecta's CEO?

Mr. Devdatt Kurdikar Ph.D. is the chief executive officer of Embecta Corp., which has about 1,850 employees.

What is the EMBC 52-week high?

The 52-week high for EMBC is $14.78 and the 52-week low is $2.77. The stock is currently 59.3% below its high.

Compare EMBC